Received Apr 22, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | UNK | — | SC / LA |
Low grade fever 99F-100F (<100.4F) started 11 days post-vaccination, lasting 2-3 days, rising to high-grade fever up to 103F for another 3-5 days, after which diffuse rash appeared and lasted for 4 days with no appetite, followed by another 3-4 days of intense vertigo (patient unable to stand or move without holding onto furniture or walls). She denied any respiratory symptoms and reported a total of ~2 weeks of symptoms that ultimately resolved 3 days before her return to clinic for planned 2nd MMR dose (was scheduled for 4/17/25). After lengthy discussion with RN and consultation with ordering physician, vaccination was postponed and titers were drawn to determine best plan of care.
4/17/25 MMR panel measles IgG >300.0 (>=16.5 immune) mumps IgG <5.0 (>10.9= immune) rubella IgG 25.6 (>0.9= immune)
cardiac anomalies:~6 months of severe, recurrent HTN episodes ~5min hourly after COVID dose #3